Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**[89Zr]-oxine-NCR100** is a radiolabeled diagnostic agent consisting of the radioactive isotope zirconium-89 (^89Zr) complexed with oxine (8-hydroxyquinoline), specifically formulated in the product *NCR100*, and is intended for in vivo cell-tracking and biodistribution studies using PET/CT imaging. The compound allows non-invasive tracking of cell therapies or labeled cell populations by enabling visualization of their distribution and kinetics in the body over time post-injection. It is currently being evaluated for the cellular distribution after local injection in knee osteoarthritis, with the main goal of quantifying uptake and organ distribution of labeled cells, providing real-time insight on cell therapy biodistribution[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [89Zr]-oxine-NCR100.